Trade

with

Acorda Therapeutics Inc
(NASDAQ: ACOR)
AdChoices
34.17
-0.84
-2.40%
After Hours :
-
-
-

Open

34.73

Previous Close

35.01

Volume (Avg)

226.10k (685.72k)

Day's Range

33.82-35.07

52Wk Range

27.51-39.95

Market Cap.

1.46B

Dividend Rate ( Yield )

-

Beta

1.37

Shares Outstanding

41.74M

P/E Ratio (EPS)

77.52 (0.45)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 336.43M

    • Net Income

    • 16.44M

    • Market Cap.

    • 1.46B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 5.37

    • PEG (Price/Earnings Growth) Ratio

    • 1.33

    • Beta

    • 1.37

    • Forward P/E

    • 27.55

    • Price/Sales

    • 4.16

    • Price/Book Value

    • 2.92

    • Price/Cash flow

    • 22.17

      • EBITDA

      • 38.03M

      • Return on Capital %

      • 2.51

      • Return on Equity %

      • 4.21

      • Return on Assets %

      • 2.51

      • Book Value/Share

      • 11.99

      • Shares Outstanding

      • 41.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 45.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • 0.24

        • Cashflow Estimate

        • 0.55

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 11.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -89.40

          • 17.04

          • Net Income

            Q/Q (last year)

          • 19.80

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 47.72

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 80.11

            • 82.75

            • Pre-Tax Margin

            • 10.65

            • 39.38

            • Net Profit Margin

            • 5.37

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 79.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -18.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.57

              • 0.76

              • Current Ratio

              • 7.33

              • 2.92

              • Quick Ratio

              • 6.69

              • 2.35

              • Interest Coverage

              • 29.07

              • 38.02

              • Leverage Ratio

              • 1.89

              • 2.21

              • Book Value/Share

              • 11.99

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 71.94

                • 243.90

                • P/E Ratio 5-Year High

                • 90.48

                • 634.30

                • P/E Ratio 5-Year Low

                • 40.65

                • 124.82

                • Price/Sales Ratio

                • 3.85

                • 9.29

                • Price/Book Value

                • 2.70

                • 8.39

                • Price/Cash Flow Ratio

                • 22.17

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 4.21

                    (3.30)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 2.51

                    (2.50)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 3.33

                    (1.90)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 45.27k

                  • 117.08k

                  • Inventory Turnover

                  • 2.24

                  • 1.48

                  • Asset Turnover

                  • 0.47

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  30.36M
                  Operating Margin
                  9.03
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  22.17
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  58.07%

                  Mutual Fund Ownership

                  60.06%

                  Float

                  85.51%

                  5% / Insider Ownership

                  2.24%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    3,478,900

                  • 0.00

                  • 8.33

                  • Eagle Small Cap Growth Fund

                  •  

                    1,178,264

                  • 0.00

                  • 2.82

                  • ClearBridge Small Cap Growth Fund

                  •  

                    891,926

                  • -1.05

                  • 2.14

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    843,539

                  • 0.57

                  • 1.92

                  • Vanguard Small Cap Index

                  •  

                    725,101

                  • -0.12

                  • 1.74

                  • Vanguard Total Stock Mkt Idx

                  •  

                    688,889

                  • 0.18

                  • 1.65

                  • Fidelity® Independence Fund

                  •  

                    650,000

                  • 0.00

                  • 1.56

                  • iShares Russell 2000 (AU)

                  •  

                    627,199

                  • -1.81

                  • 1.43

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    613,487

                  • 0.00

                  • 1.47

                  • iShares Nasdaq Biotechnology

                  •  

                    542,639

                  • -0.24

                  • 1.24

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    6,297,690

                  • +73.85%

                  • 15.09

                  • Vanguard Group, Inc.

                  •  

                    2,781,919

                  • +0.32%

                  • 6.78

                  • BlackRock Fund Advisors

                  •  

                    2,652,333

                  • -5.10%

                  • 6.46

                  • Eagle Asset Management, Inc.

                  •  

                    2,472,471

                  • +3.39%

                  • 5.92

                  • Oracle Investment Management Inc

                  •  

                    1,931,414

                  • -1.28%

                  • 4.70

                  • UBS Global Asset Mgmt Americas Inc

                  •  

                    1,586,196

                  • +12.67%

                  • 3.86

                  • State Street Corp

                  •  

                    1,314,725

                  • -5.39%

                  • 3.20

                  • Wellington Management Company, LLP

                  •  

                    1,229,991

                  • +4.43%

                  • 3.00

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Acorda Therapeutics, Inc. was incorporated on March 17, 1995 as a Delaware corporation. It is a biopharmaceutical company, engaged in the identification, development and commercialization of novel therapies that improve neurological ...morefunction in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a shor...moret-acting drug approved by the FDA for the management of spasticity. The Company is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for “Fampyra” and “Kampyra” and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" and “Qutenza” in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.lessless

                  Key People

                  Ron Cohen,M.D.

                  CEO/Chairman of the Board/Director/Founder/President

                  Michael W. Rogers

                  CFO/Chief Accounting Officer

                  Lauren M. Sabella

                  Executive VP, Divisional

                  Mr. Lorin Jeffry (Jeff) Randall

                  Director

                  Steven M. Rauscher

                  Director

                  • Acorda Therapeutics Inc

                  • 420 Saw Mill River Road

                  • Ardsley, NY 10502

                  • USA.Map

                  • Phone: +1 914 347-4300

                  • Fax: +1 914 347-4560

                  • acorda.com

                  Incorporated

                  1995

                  Employees

                  421

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: